BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) awarded an inducement grant to a new employee as part of its 2025 Inducement Plan [1][3] - The inducement grant includes non-qualified stock options for 53,060 shares at an exercise price of $12.88 per share, with a vesting schedule [2] - The awards were approved by an independent compensation committee and are intended to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4) [3] Company Overview - BBOT is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies [4] - The company aims to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors [4]